ArticleJournal of thyroid research2012
Thyroid cancer: molecular aspects and new therapeutic strategies.
Article in Journal of thyroid research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.Signal transduction and targeted therapy · 2024Trial
- Trial
- How to manage radioiodine-refractory thyroid cancer in the era of precision medicine.Drugs in context · 2026Review
- Synergizing Success: The Role of Anlotinib Combinations in Advanced Non-Small Cell Lung Cancer Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Changes in peripheral blood immune cell population in thyroid cancer patients treated with lenvatinib.Scientific reports · 2023Article
- Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial.Frontiers in oncology · 2022Article
- The role of microRNAs in the pathogenesis of thyroid cancer.Non-coding RNA research · 2020Review
- Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria.International journal of endocrinology · 2020Article
- Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer.Cancers · 2019Article
- Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Review
- Lenvatinib for Anaplastic Thyroid Cancer.Frontiers in oncology · 2017Article
- Neoadjuvant Therapy in Differentiated Thyroid Cancer.International journal of surgical oncology · 2016Review
- Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2015Review
- Expression of YY1 in Differentiated Thyroid Cancer.Endocrine pathology · 2015Article
- Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice.Endocrine · 2015Article
- The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients.International journal of endocrinology · 2015Article
- Thyroid cancer: SEOM clinical guidelines.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2014Article
- Molecular profiling of thyroid cancer subtypes using large-scale text mining.BMC medical genomics · 2014Article
- Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib.Biologics : targets & therapy · 2014Review
- Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma.International journal of endocrinology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite that thyroid cancer accounts for over 90% of tumors that arise from the endocrine system, these tumors barely represent 2% of solid tumors in adults. Many entities are grouped under the general term of thyroid cancer, and they differ in histological features as well as molecular and clinical behavior. Thus, the prognosis for patients with thyroid cancer ranges from a survival rate of >97% at 5 years, in the case of differentiated thyroid tumors sensitive to radioactive iodine, to a 4-month median survival for anaplastic tumors. The high vascularity in these tumors and the important role that oncogenic mutations may have in the RAS/RAF/MEK pathway and oncogenicity (as suggested by activating mutations and rearrangements of the RET gene) have led to the development of multitarget inhibitors in different histological subgroups of patients. The correct molecular characterization of patients with thyroid cancer is thought to be a key aspect for the future clinical management of these patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.